Impact BioMedical, Inc. Cash Flow-to-Debt Ratio
Impact BioMedical, Inc. cash flow-to-debt ratio. Impact BioMedical, Inc. (IBO) has a Cash Flow-to-Debt Ratio of -0.07x as of September 2025, meaning its operating cash flow of $-1.99 Million could theoretically repay 0% of its total liabilities ($27.06 Million) in one year. Check Impact BioMedical, Inc. investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Impact BioMedical, Inc. (2017–2024)
Cash flow-to-debt ratio of Impact BioMedical, Inc. from 2017 to 2024. Historical debt coverage capacity for Impact BioMedical, Inc. across 8 annual periods. Check earnings quality score of Impact BioMedical, Inc. to evaluate the quality of earnings relative to operating cash generation.
Impact BioMedical, Inc. Cash Flow-to-Debt Ratio by Year (2017–2024)
Impact BioMedical, Inc. cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Impact BioMedical, Inc.. For the full cash flow conversion analysis, see IBO operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.43x | $-5.64 Million | $13.05 Million | ▼ -147.9% |
| 2023 | -0.17x | $-2.85 Million | $16.37 Million | ▲ +44.4% |
| 2022 | -0.31x | $-4.33 Million | $13.83 Million | ▲ +89.9% |
| 2021 | -3.10x | $-3.25 Million | $1.05 Million | ▼ -21070.9% |
| 2020 | -0.01x | $-1.14K | $78.03K | ▲ +99.7% |
| 2019 | -5.62x | $-121.98K | $21.72K | ▼ -56.7% |
| 2018 | -3.58x | $-71.99K | $20.09K | ▲ +71.5% |
| 2017 | -12.59x | $-320.34K | $25.44K | — |